UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 5, 2013

 

ARTHROCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-34607

 

94-3180312

(State or other jurisdiction
 of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification
Number)

 

7000 West William Cannon, Building One

Austin, TX

(Address of principal executive offices, including zip code)

 

(512) 391-3900

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 7.01 — Regulation FD Disclosure

 

Effective September 5, 2013, James L. Pacek, our Senior Vice President of Global Markets and Sales Operations, entered into a new prearranged trading plan.  Subject to certain conditions precedent, the trading plan provides for the exercise and sale of 20,694 stock options and 2,500 shares of common stock in one or more open market transactions between October 7, 2013 and April 7, 2014.  Such transactions will occur only upon satisfaction of the trading plan’s conditions precedent.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ARTHROCARE CORPORATION

 

 

 

 

 

Date: September 9, 2013

By:

/s/ David Fitzgerald

 

 

David Fitzgerald

 

 

President and Chief Executive Officer

 

3